Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Among authors: uboha nv. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.
A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.
Witt JS, Kuczmarska-Haas A, Lubner M, Reeder SB, Cho SY, Minter R, Weber S, Ronnekleiv-Kelly S, Abbott D, LoConte N, Mulkerin DL, Lubner SJ, Uboha NV, Deming D, Ritter MA, Mohindra P, Bassetti MF. Witt JS, et al. Among authors: uboha nv. Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):458-463. doi: 10.1016/j.ijrobp.2020.09.010. Epub 2020 Sep 14. Int J Radiat Oncol Biol Phys. 2021. PMID: 32942002 Clinical Trial.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. Naing A, et al. J Immunother Cancer. 2021 Jul;9(7):e002447. doi: 10.1136/jitc-2021-002447. J Immunother Cancer. 2021. PMID: 34301809 Free PMC article.
Adjuvant Chemotherapy for Stage II Rectal Cancer.
Deming D, Uboha N, Zafar SY, Rosenberg S, Bassetti M, Glasgow S, Borden EC, Lubner S. Deming D, et al. Semin Oncol. 2015 Dec;42(6):e99-107. doi: 10.1053/j.seminoncol.2015.09.033. Epub 2015 Sep 21. Semin Oncol. 2015. PMID: 26615141 Review. No abstract available.
TAS-102: a novel antimetabolite for the 21st century.
Uboha N, Hochster HS. Uboha N, et al. Future Oncol. 2016 Jan;12(2):153-63. doi: 10.2217/fon.15.276. Epub 2015 Nov 30. Future Oncol. 2016. PMID: 26616466 Free PMC article. Review.
32 results